Clinical Trial Update: A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement [Phase 2]

View source ↗

Summary

Phase II trial evaluating the combination of pemigatinib and durvalumab in previously treated advanced intrahepatic cholangiocarcinoma with FGFR2 rearrangement;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• IMFINZI (DURVALUMAB)
• Pemazyre (pemigatinib)

Snippet

Sponsor: Mehmet Akce | Conditions: Intrahepatic Cholangiocarcinoma, FGFR2 Gene Rearrangement | Phase 2 | Status: RECRUITING